FinTechFunding

Noxopharm: Announces novel mRNA “vaccine enhancer” product

Noxopharm Announces novel mRNA “vaccine enhancer” product

  • Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation
  • The company says it has selected a lead candidate for further development, and the product — dubbed SOF-VAC — will be part of its Sofra preclinical platform
  • NOX says SOF-VAC is the smallest known molecule of its type to have demonstrated “strong activity” against inflammation
  • The company is developing the product in partnership with the Hudson Institute of Medical Research
  • Shares in the company are up 3.16 per cent to 9.8 cents at midday AEDT
Previous article
Raisin: Announces €60 million funding
Next article
eToro: Announces major charting upgrade in partnership with TradingView
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...
FinTech

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...